Strong Growth In Foreign Trade Of Biological Medicinal Products Is The Main Market In Asia

{pixabay|100|campaign}

Biomedical products refers to the micro-organisms, parasites, animal toxins, biological tissue as starting material, purified by a biological process or technical preparation, technology and analysis of biological control of the quality of intermediate products and finished products made from bio-active agents, such as plague (bacteria) vaccine, toxin, toxoid, immune serum, blood products, immunoglobulin, antigen, allergen, and cytokines.

In the current customs Export Tariff, it is also no uniform, clear tariff biomedicine, genetic engineering, biological medicine, such as vaccines, monoclonal antibodies, interferon and blood products and other imports and exports, usually through under the customs tariff 3002. Therefore, data on national statistics, biomedical difficult to fully reflect China’s actual situation of import and export of biological medicine. No doubt, China will show strong growth in import and export of bio-medicine momentum.

2009, China’s import and export amount of biomedical 887 million U.S. dollars, up 44.35%, of which exports grew 53.16 percent, exports grew 19.71% vaccine

Import and export of China is facing biomedical development of better opportunities, strong government support, China’s bio-pharmaceutical industry has made great progress, and international bio-pharmaceutical industry are becoming increasingly close, in keeping Biomedical Import Substantial growth, a number of biomedical exports are growing steadily.

2009, China’s import and export amount of biomedical 887 million U.S. dollars, up 44.35 percent. Among them, the exports 87,175,000 US dollars, up 53.16 percent; imports amounted to 800 million US dollars, up 43.35%, imports and exports showed a dramatic upward trend, the development of potentially very strong. At present, China Bio Pharmaceutical Industry Has been developed to more than 500 biological pharmaceutical industry more than 40 billion yuan sales income, but lower than the global bio-pharmaceutical industry in the pharmaceutical industry in the proportion of biomedical industry in China also shows a very large room for development. Can be expected: in 2010 China’s import and export of bio-medicine will continue to maintain high growth.

Export Asia is the main market, a major breakthrough in vaccine

Company in 2009, engaged in biomedical Drugs Exports total 135 enterprises, exports of 100 million or more enterprises have 20, the Chengdu Institute of Biological Products, Ed Inspection Technologies Co., Ltd., Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Co., Ltd. four Chuanke Lun Biomedical Company Limited, ABON (Hangzhou) Co., Ltd., of Lanzhou Biological Technology Development Co., Ltd., Shanghai Branch of China and Bioengineering Co., Ltd. Liaoning, and Sichuan Yuanda Cheng Kung University Biological Pharmaceutical Co., Shu Yang China biomedical companies, among the top 10 exports, up 59.66 percent share.

Market In 2009, total exports to China Biological Medicine 126 countries and regions, Asia is the main export market share as high as 59.57 percent. In 2009, China’s top ten trading partners, exports of bio-medicine followed by India, the United States, China, Hong Kong, Canada, Egypt, Ethiopia, Vietnam, Indonesia, Thailand and Pakistan, the proportion reached 77.99%, of which only the Indian market share as high as 34.66%.

Varieties in 2009, China’s human vaccine exports 19,157,600 U.S. dollars, up 19.71 percent, were exported to 35 countries and regions, Oceania and North America did not export records, the main export markets India, Pakistan, South Korea, Malawi and Thailand, up 84.63 percent share, of which India’s share is only as high as 67.39%.

20 enterprises in China engaged in export of human vaccines, Chengdu Institute of Biological Products, Biological Co., Ltd. Liaoning Cheng Kung University, Changchun Institute of Biological Products Import & Export Department, Shenzhen City Industrial Development Co., Ltd. Main Gao, Changchun Chang Sheng Biotechnology Co., Ltd. rank in 2009 exports of vaccines for human use the top five, up 87.19 percent share, of which only the proportion of the Chengdu Institute of Biological Products as high as 45.92 percent.

The new century, with SARS, H5N1, H1N1 and other viruses turns raging, all kinds of Epidemic The trend was spreading around the world, making a substantial increase in demand for the vaccine market, according to forecasts, the global vaccine market sales will increase rate of 18%, 2011, the global vaccine market sales will grow to 30 billion U.S. dollars.

Inexpensive vaccine as China, in Asia, Africa, popular market and maintain the momentum of rapid growth. Chengdu Institute of Biological Products Over the years, successfully passed the review of the Indian drug regulatory departments, its own intellectual property rights of JE vaccine into the government procurement system in India, marking China’s biomedical industry has been greatly improved, but In addition to outside of Chengdu Institute of Biological Products, no other domestic enterprises to enter the foreign government procurement area.